{"id":754290,"date":"2023-05-03T09:09:17","date_gmt":"2023-05-03T13:09:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/"},"modified":"2023-05-03T09:09:17","modified_gmt":"2023-05-03T13:09:17","slug":"alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/","title":{"rendered":"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">HOUSTON, May  03, 2023  (GLOBE NEWSWIRE) &#8212; Alaunos Therapeutics, Inc. (\u201cAlaunos\u201d or the \u201cCompany\u201d) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update.<\/p>\n<p align=\"justify\">Register for the live webcast using the link <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vpYAjxYqkzguMK0WZnkDWAKIhDiKAKEonZNty-QJZVcdJ8nKjn7DURi97FXIBDxAFCBQtd4-BbOyp7xdIdjxtQJjNVLumPF0ZHH_PJ93hls=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a> or by visiting the \u201cInvestors\u201d section of the Alaunos website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VYgJJrTVdX9Z1NdUnOJ_1jN-wElyCBjxNF0iCMbzxt0EeaWugn9wBXxCyJiMtWpBRt7oIx4iC_Q3VxSG-v7d3Q==\" rel=\"nofollow noopener\" target=\"_blank\">www.alaunos.com<\/a>. To participate via telephone, please register in advance at this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZmgUdqqRcnxV4JGW3gJztfsZdigbkHhogxvlp-meR8eMbiebk_kpU_-9EkaowHVHlkX2ncCJQKguO8DyLCyDynK6PnTaYdvmk7IpIixdwdsOnH_pJsOP0j01PVrzSCiXCy_lupgBY0MnbABUYHnnkQ==\" rel=\"nofollow noopener\" target=\"_blank\">link<\/a>. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The event will be archived on the Company\u2019s website for approximately 30 days after the call.<\/p>\n<p align=\"justify\">\n        <strong>About Alaunos Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Alaunos Therapeutics is a leader in the science of T-cell receptor (TCR) cell therapy working to revolutionize solid cancer treatment and outcomes. The clinical-stage company\u2019s TCR T-cell therapy (TCR-T) is one of the most advanced TCR programs targeting driver mutations in solid tumors with an ongoing Phase 1\/2 trial of its TCR-T product candidates across six solid cancers. Alaunos is powered by two proprietary platforms: its elegantly efficient non-viral <em>Sleeping Beauty<\/em> cell engineering platform; and its hunTR<sup>\u00ae<\/sup> discovery platform, which is expanding its industry-leading library of TCRs against high-frequency driver mutations. Alaunos is a part of an ongoing collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), working to advance the science of TCR therapy. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VYgJJrTVdX9Z1NdUnOJ_1h1HauvyLPDSfyPx-ytHa_zFm2r36M9wYaRL2kJ4RuJLJfOIle6Rtv3VBOYxezd6hzA31f7exjXSSRgPLXRF7Fq1Hci4xCH8ca7nkyzOraVN-9yMn8MmqrHjwyyNF7a7BwbLxXzOAtJagzwHGjvXzlBQimvja5Zv3rgTUI-SgKCAHPd2YtNlhB2lkXPkRf0E0HSpWTLOFb_Lc4N0uZXVMj8=\" rel=\"nofollow noopener\" target=\"_blank\">www.alaunos.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Alex Lobo<br \/>Stern Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IVfPmAfvNMPtyHYOszg-nS1Ai__ZUVJt2pEZCNeO64vIX22ZPf8q75hGHg1E1Zq8u84TRS0FqU9dL6lLSwumXYt7ZlGzxc8y0GuskV4L2zI=\" rel=\"nofollow noopener\" target=\"_blank\">Alex.lobo@sternir.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Heather Anderson<br \/>6 Degrees PR<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VREaFP2JD7YawoRdkWxIjSJ_nWQUjpvgQaI23A8PrqzzWUYWJT7dvOpyGwpNQsnR0XKv8bJAusZyQTLQxCAZTxQz7wSk45JsfM-82UdQ_5I=\" rel=\"nofollow noopener\" target=\"_blank\">handerson@6degreespr.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWY5MmMxMWUtMzMxYi00OGFiLWFlYTItMzhjNWNhNjIyNTMxLTEwMTkxMjM=\/tiny\/Alaunos-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) &#8212; Alaunos Therapeutics, Inc. (\u201cAlaunos\u201d or the \u201cCompany\u201d) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the \u201cInvestors\u201d section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at this link. Upon registration, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754290","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) &#8212; Alaunos Therapeutics, Inc. (\u201cAlaunos\u201d or the \u201cCompany\u201d) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the \u201cInvestors\u201d section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at this link. Upon registration, &hellip; Continue reading &quot;Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-03T13:09:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023\",\"datePublished\":\"2023-05-03T13:09:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/\"},\"wordCount\":330,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/\",\"name\":\"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA=\",\"datePublished\":\"2023-05-03T13:09:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/","og_locale":"en_US","og_type":"article","og_title":"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 - Market Newsdesk","og_description":"HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) &#8212; Alaunos Therapeutics, Inc. (\u201cAlaunos\u201d or the \u201cCompany\u201d) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the \u201cInvestors\u201d section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at this link. Upon registration, &hellip; Continue reading \"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-03T13:09:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023","datePublished":"2023-05-03T13:09:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/"},"wordCount":330,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/","name":"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA=","datePublished":"2023-05-03T13:09:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDQ4MSM1NTcwOTQ1IzIwMDc1NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754290"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754290\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}